336 related articles for article (PubMed ID: 18615600)
1. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Chamberlain MC; Johnston SK
Cancer; 2009 Oct; 115(20):4775-82. PubMed ID: 19569246
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Tsao-Wei DD; Groshen S
Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Chamberlain MC
J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
8. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of temozolomide in children with recurrent high-grade glioma.
Ruggiero A; Cefalo G; Garré ML; Massimino M; Colosimo C; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mazzarella G; Caldarelli M; Di Rocco C; Madon E; Abate ME; Clerico A; Sandri A; Riccardi R
J Neurooncol; 2006 Mar; 77(1):89-94. PubMed ID: 16292488
[TBL] [Abstract][Full Text] [Related]
14. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide for treatment-resistant recurrent meningioma.
Chamberlain MC; Tsao-Wei DD; Groshen S
Neurology; 2004 Apr; 62(7):1210-2. PubMed ID: 15079029
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Chamberlain MC; Colman H; Kim BT; Raizer J
J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
[TBL] [Abstract][Full Text] [Related]
18. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]